0001493152-22-023168.txt : 20220816 0001493152-22-023168.hdr.sgml : 20220816 20220816144234 ACCESSION NUMBER: 0001493152-22-023168 CONFORMED SUBMISSION TYPE: S-8 PUBLIC DOCUMENT COUNT: 7 FILED AS OF DATE: 20220816 DATE AS OF CHANGE: 20220816 EFFECTIVENESS DATE: 20220816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Processa Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001533743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 451539785 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-266912 FILM NUMBER: 221169664 BUSINESS ADDRESS: STREET 1: 7380 COCA COLA DRIVE STREET 2: SUITE 106 CITY: HANOVER STATE: MD ZIP: 21076 BUSINESS PHONE: 443-776-3133 MAIL ADDRESS: STREET 1: 7380 COCA COLA DRIVE STREET 2: SUITE 106 CITY: HANOVER STATE: MD ZIP: 21076 FORMER COMPANY: FORMER CONFORMED NAME: Heatwurx, Inc. DATE OF NAME CHANGE: 20111028 S-8 1 forms-8.htm

 

As filed with the Securities and Exchange Commission on August 16, 2022

 

Registration No. 333-

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

 

Processa Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   7380 Coca Cola Drive, Suite 106   45-1539785
(State or other jurisdiction of   Hanover, MD 21076   (I.R.S. Employer
incorporation or organization)   (Address of Principal Executive Offices)   Identification No.)

 

Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan

(Full title of the plan)

 

David Young, Pharm.D., Ph.D.

Chief Executive Officer

7380 Coca Cola Drive, Suite 106

Hanover, MD 21076

443-776-3133

(Name, address and telephone number of agent for service)

 

Copy to:

Michael B. Kirwan

John J. Wolfel, Jr.

Foley & Lardner LLP

One Independent Drive, Suite 1300

Jacksonville, Florida 32202

(904) 359-2000

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 

 

 

 

EXPLANATORY NOTE

 

The purpose of this Registration Statement is to register 3,000,000 additional shares of common stock, par value $0.0001 per share (the “Common Stock”), of Processa Pharmaceuticals, Inc. (the “Company”) in connection with the Company’s 2019 Omnibus Incentive Plan.

 

Pursuant to General Instruction E of Form S-8, the contents of the Company’s prior Registration Statements on Form S-8 (Registration No. 333-233264) and Form S-8 (Registration No. 333-257557), including the documents incorporated by reference therein, are incorporated by reference into this Registration Statement, except as set forth below.

 

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents by Reference.

 

The contents of the following documents, which have previously been filed by the Company with the Securities and Exchange Commission (the “SEC”), are hereby incorporated in this Registration Statement by reference:

 

Our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 30, 2022 and amended on May 2, 2022;
   
Our Proxy Statement on Schedule 14A for the 2022 Annual Meeting of Stockholders, filed with the SEC on May 31, 2022;
   
Our Quarterly reports on Form 10-Q for the quarter ended March 31, 2022, filed with the SEC on May 12, 2022 and for the quarter ended on June 30, 2022, filed with the SEC on August 11, 2022;
   
Our Current Reports on Form 8-K filed with the SEC on January 6, 2022, March 24, 2022, May 16, 2022, July 14, 2022 and July 25, 2022; and
   
the description of our common stock contained in or incorporated into our Registration Statement on Form 8-A, filed September 17, 2020, and any amendment or report updating that description.

 

Notwithstanding the foregoing, documents or portions thereof containing information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits under Item 9.01, are not incorporated by reference in this prospectus.

 

Item 5. Interests of Named Experts and Counsel.

 

The validity of the securities offered by this prospectus will be passed upon for us by Foley & Lardner LLP.

 

2/4

 

 

Item 8. Exhibits.

 

Exhibit Number   Description
4.1   Amended and Restated Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Annex A to the Company’s definitive proxy statement filed on May 31, 2022)
     
4.2   Fourth Amended and Restated Certificate of Incorporation of Heatwurx, Inc. (incorporated herein by reference to Exhibit 3.1 to the Form S-1/A filed with the SEC on September 16, 2020)
     
4.3   Amendment to Fourth Amended and Restated Certificate of Incorporation of Heatwurx, Inc. (incorporated herein by reference to Exhibit 3.1.1 to the Form S-1/A filed with the SEC on September 16, 2020)
     
4.4   Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1.2 to Form S-1/A filed on September 16, 2020)
     
4.5   Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation dated August 8, 2019 (incorporated herein by reference to Exhibit 3 to Form 10-Q filed on August 14, 2019)
     
4.6   Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation dated December 23, 2019 (incorporated herein by reference to Exhibit 3.1.3 to Form S-1/A filed on September 16, 2020)
     
4.7   Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation of Processa Pharmaceuticals, Inc. dated June 25, 2020 (incorporated herein by reference to Exhibit 3.1.4 to the Form S-1/A filed with the SEC on September 16, 2020)
     
4.8   Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation dated January 1, 2022 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 6, 2022)
     
4.9   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Form S-1/A filed with the SEC on September 16, 2020)
     
5.1   Legal Opinion of Foley & Lardner LLP (filed herewith)
     
23.1   Consent of Independent Registered Public Accounting Firm, BD & Co. Inc. (filed herewith)
     
23.2   Consent of Foley & Lardner LLP (included as part of its opinion filed as Exhibit 5.1 hereto)
     
107.1   Filing Fee Table (filed herewith)

 

3/4

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Hanover, State of Maryland, on this 16th day of August 2022.

 

 

PROCESSA PHARMACEUTICALS, INC.

 

 

 

By: /s/ David Young

 

 

David Young                  

 

 

President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons on August 16, 2022 in the capacities indicated.

 

Signature   Title
     
/s/ David Young   President and Chief Executive Officer
David Young   (Principal Executive Officer)
     
/s/ James Stanker   Chief Financial Officer
James Stanker   (Principal Financial Officer and Principal Accounting Officer)
     
/s/ Justin Yorke   Chairman of the Board of Directors
Justin Yorke    
     
/s/ Khoso Baluch   Director
Khoso Baluch    
     
/s/ James R. Neal   Director
James R. Neal    
     
/s/ Geraldine Pannu   Director
Geraldine Pannu    
     

/s/ Virgil Thompson

  Director
Virgil Thompson    

 

4/4

 

EX-5.1 2 ex5-1.htm

 

Exhibit 5.1

 

ATTORNEYS AT LAW LLP

ONE INDEPENDENT DRIVE, SUITE 1300

JACKSONVILLE, FL 32202-5017

904.359.2000 TEL

904.359.8700 FAX

WWW.FOLEY.COM

 

  August 16, 2022

 

Processa Pharmaceuticals, Inc.

7380 Coca Cola Drive, Suite 106

Hanover, Maryland 21076

 

  Re: Registration Statement on Form S-8

 

Ladies and Gentlemen:

 

We have acted as counsel to Processa Pharmaceuticals, Inc. a Delaware corporation (the “Company”), in connection with the Company’s filing of a Registration Statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Act”). The Registration Statement relates to the registration of the offer, issuance and sale by the Company of 3,000,000 shares of common stock, par value $0.0001 per share (the “Securities”) of the Company. The Securities are to be sold by the Company pursuant to the Company’s Amended and Restated 2019 Omnibus Incentive Plan (the “Plan”), incorporated by reference as Exhibit 4.1 to the Registration Statement.

 

As counsel to the Company, we have examined the Certificate of Incorporation of the Company, as amended, the amended and restated Bylaws of the Company, the Plan, the Registration Statement and such corporate records, documents, agreements and such matters of law as we have considered necessary or appropriate for the purpose of this opinion. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity with the originals of all documents submitted to us as copies.

 

Based upon the foregoing and subject to the qualifications set forth herein, we are of the opinion that the Securities have been duly authorized and, when issued and delivered upon the receipt of consideration constituting lawful consideration under Delaware law in accordance with the Plan, will be validly issued, fully paid and non-assessable.  

 

Our opinion is limited to the laws of Delaware and federal laws of the United States of America to the extent referred to specifically herein, in each case as are, in our professional judgment, applicable to transactions of the type contemplated by the Registration Statement, and we do not express any opinion herein concerning any other laws, statutes, ordinances, rules or regulations. This opinion letter is rendered as of the date hereof, and we make no undertaking, and expressly disclaim any duty, to supplement or update this opinion letter or the opinion expressed herein, if, after the date of this opinion letter, facts and/or circumstances come to our attention, and/or changes in the law occur, which would affect such opinion.

 

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to any reference to our firm in the prospectus which is a part of the Registration Statement. In giving this consent, we do not hereby admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules or regulations of the Securities Exchange Commission promulgated thereunder. 

 

  Sincerely,
   
  /s/ FOLEY & LARDNER LLP

 

AUSTIN

Boston

CHICAGO

dallas

DENVER

DETROIT

houston

JACKSONVILLE

LOS ANGELES

MADISON

MEXICO CITY

MIAMI

MILWAUKEE

NEW YORK

ORLANDO

SACRAMENTO

SAN DIEGO

SAN FRANCISCO

SILICON VALLEY

TALLAHASSEE

TAMPA

WASHINGTON, D.C.

BRUSSELS

TOKYO

 

 

 

EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report, dated March 30, 2022, with respect to the audited consolidated financial statements of Processa Pharmaceuticals, Inc. for the years ended December 31, 2021 and 2020 included in the Annual Report on Form 10-K, as amended, of Processa Pharmaceuticals, Inc. for the year ended December 31, 2021.

 

/s/ BD & Company, Inc.

 

Owings Mills, MD

August 16, 2022

 

 

 

 

EX-FILING FEES 4 ex107.htm CALCULATION OF FILING FEE TABLES

 

Exhibit 107

 

Calculation of Filing Fee Tables

 

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

 

Processa Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

 

Table 1: Newly Registered Securities

 

Security Type  Security Class Title  Fee
Calculation Rule
  Amount Registered(1)   Proposed Maximum Offering Price Per Unit(2)   Maximum Aggregate Offering Price(2)   Fee Rate   Amount of Registration Fee 
Equity  Common Stock, par value $0.0001 per share  Other(2)   3,000,000(1)  $3.14(2)  $9,420,000(2)   0.0000927   $873.24 
Total Offering Amounts    -   $9,420,000    -   $873.24 
Total Fee Offsets    -    -    -   $- 
Net Fee Due    -    -    -   $873.24 

 

(1) Represents shares of common stock, par value $0.0001 per share (“Common Stock”) of Processa Pharmaceuticals, Inc. (the “Registrant”). Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the amount to be registered includes any additional shares of the Registrant’s Common Stock that become issuable under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan, as amended and restated, by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant’s Common Stock, as applicable.
   
(2) Determined on the basis of the average of the high and low sale price of Common Stock as reported on the Nasdaq Stock Market on August 12, 2022 of $3.14, solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act.

 

 

 

GRAPHIC 5 ex5-1_1.jpg begin 644 ex5-1_1.jpg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end GRAPHIC 6 image_001.jpg begin 644 image_001.jpg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ⅅ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ex23-1_2.jpg begin 644 ex23-1_2.jpg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end